Inventor · disambiguated record
Amogh Boloor
Also filed as: BOLOOR AMOGH
34 granted patents·7 pending applications·266 citations·filing 2001–2024
97Inventor score
Files withCELGENE QUANTICEL RES INC28BOLOOR AMOGH3QUANTICEL PHARMACEUTICALS INC3SMITHKLINE BEECHAM CORP3GENENTECH INC2
Top patents by PatentIndex Score
41 records- 0198US9242968B2Histone demethylase inhibitorsQUANTICEL PHARMACEUTICALS INC·Filed 2015·Granted Jan 26, 2016·17 cites·28 claims
- 0295US10941160B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2020·Granted Mar 9, 2021·3 cites·25 claims
- 0395US10023592B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2017·Granted Jul 17, 2018·11 cites·27 claims
- 0495US9643965B2Histone demethylase inhibitorsQUANTICEL PHARMACEUTICALS INC·Filed 2015·Granted May 9, 2017·6 cites·5 claims
- 0595US7105530B2Pyrimidineamines as angiogenesis modulatorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 12, 2006·72 cites·10 claims
- 0694US11535616B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2020·Granted Dec 27, 2022·2 cites·13 claims
- 0794US9034900B2Bromodomain inhibitorsQuanticel Pharmaceuticals·Filed 2014·Granted May 19, 2015·36 cites·30 claims
- 0894US7262203B2Pyrimidineamines as angiogenesis modulatorsSMITHKLINE BEECHAM CORP·Filed 2006·Granted Aug 28, 2007·32 cites·50 claims
- 0993US10112940B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2017·Granted Oct 30, 2018·4 cites·6 claims
- 1093US9598372B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2015·Granted Mar 21, 2017·10 cites·31 claims
- 1193US9586902B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2016·Granted Mar 7, 2017·5 cites·30 claims
- 1292US10815234B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2020·Granted Oct 27, 2020·2 cites·9 claims
- 1392US10208039B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Feb 19, 2019·4 cites·8 claims
- 1492US10202381B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Feb 12, 2019·4 cites·24 claims
- 1592US9815828B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2017·Granted Nov 14, 2017·4 cites·36 claims
- 1691US10030017B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2016·Granted Jul 24, 2018·4 cites·4 claims
- 1791US9447046B2Histone demethylase inhibitorsQUANTICEL PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·4 cites·26 claims
- 1891US8114885B2Chemical compoundsBOLOOR AMOGH·Filed 2007·Granted Feb 14, 2012·22 cites·19 claims
- 1990US2025066355A1Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2024·Application pending·0 cites
- 2089US11020380B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2020·Granted Jun 1, 2021·2 cites·27 claims
- 2189US10611763B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Apr 7, 2020·2 cites·7 claims
- 2288US11890275B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2021·Granted Feb 6, 2024·1 cites·44 claims
- 2388US2024182490A1Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2023·Application pending·0 cites
- 2485US12172998B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2022·Granted Dec 24, 2024·0 cites·13 claims
- 2585US10807982B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2019·Granted Oct 20, 2020·2 cites·14 claims
- 2685US10617680B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2018·Granted Apr 14, 2020·3 cites·48 claims
- 2785US9908885B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2016·Granted Mar 6, 2018·4 cites·24 claims
- 2884US10562915B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Feb 18, 2020·2 cites·12 claims
- 2983US10106534B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Oct 23, 2018·1 cites·25 claims
- 3083US9994561B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2017·Granted Jun 12, 2018·1 cites·35 claims
- 3181US2024293381A1Therapeutic CompoundsCELGENE QUANTICEL RES INC·Filed 2024·Application pending·0 cites
- 3279US7858626B2Pyrimidineamines as angiogenesis modulatorsGLAXOSMITHKLINE LLC·Filed 2007·Granted Dec 28, 2010·3 cites·20 claims
- 3376US11884680B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2020·Granted Jan 30, 2024·0 cites·14 claims
- 3476US10494371B2Bromodomain inhibitorsCELGENE QUANTICEL RES INC·Filed 2018·Granted Dec 3, 2019·1 cites·31 claims
- 3575US10385047B2Histone demethylase inhibitorsCELGENE QUANTICEL RES INC·Filed 2015·Granted Aug 20, 2019·1 cites·27 claims
- 3675US2025115618A1Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2024·Application pending·0 cites
- 3771US10202360B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2017·Granted Feb 12, 2019·1 cites·29 claims
- 3869US2010105712A1Chemical compoundsSMITHKLINE BEECHAM CORP·Filed 2009·Application pending·0 cites
- 3961US12234245B2Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Granted Feb 25, 2025·0 cites·19 claims
- 4057US2012277258A1Chemical CompoundsBOLOOR AMOGH·Filed 2012·Application pending·0 cites
- 4142US2006252943A1Chemical processBOLOOR AMOGH·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Amogh Boloor files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →